News | Cath Lab | June 22, 2017

Vascular Solutions Recalls Venture Catheters That May Split or Separate During Use

FDA identified this as a Class 1 recall due to the possibility of components embolizing

The Vascular Solutions Venture catheters were recalled due to tip separation

June 22, 2017 — The U.S. Food and Drug Administration (FDA) has identified Vascular Solutions’ recent recall of its Venture catheters as a Class I recall, it announced this week. This is the most serious type of recall, because the FDA said use of these devices may cause serious injuries or death.

Vascular Solutions initiated a voluntary recall of the guidewires April 25, 2017. The company said there is a risk of the catheter tip splitting or separating during use. Excess material at the tip of the catheter may separate and could embolize into the patient's bloodstream. This can result in serious adverse health consequences such as the development of blood clots, embolism of the excess material to vital organs, or death.

Recall is for Venture RX Catheter (Model 5820), Venture OTW (Model 5821) and Venture CS  Catheter (Model 5822). These devices were distribution between May 7, 2015 to April 19, 2017, and manufactured between May 7, 2015 to March 31, 2017. The recall includes 7,054 nationwide in the U.S.

The Venture catheter is intended for directing, steering, controlling and supporting a guidewire to access veins and arteries in the arms, legs, hands, feet, and heart muscle (myocardium). Certain models may also administer saline fluids or drugs into blood vessels.

The company sent an urgent medical device recall letter to all affected customers. The letter asked distributors and customers to identify and remove any affected Venture catheters from inventory and quarantine. This includes completing a field safety notice and a customer inventory form. After all the affected catheters are returned, customers are asked to complete the Vascular Solutions Inc. Distributor Inventory Form, and return it via email to [email protected] Upon receipt of the form, Vascular Solutions' customer service department will provide a return authorization number and arrange for return of affected Venture catheters. A credit will be offered after affected devices have been returned, the company said.

Healthcare professionals and consumers may contact Vascular Solutions at (888) 240-6001 Monday through Friday, between the hours of 8 a.m. and 5 p.m. Central Time, or by e-mail at [email protected] with any questions related to this recall.

For a complete list of recalled product codes and lot numbers go to www.fda.gov/MedicalDevices/Safety/ListofRecalls/ucm564092.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Related Content:

VIDEO: Basics of Interventional Guidewire Design and Function

Understanding the Design and Function of Guidewire Technology

The Basics of Guide Wire Technology

 

Related Content

News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
Subscribe Now